Med Life (BSE:M) Beta: 0.3573 (As of Jun. 24, 2026)


BSE:M Med Life SA BSE:M
90 GF Score
Price lei11.36
GF Value lei7.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Med Life Beta?

Med Life BSE:M +0.53% 90 Beta is 0.3573 as of Jun. 24, 2026. GuruFocus rates BSE:M with a GF Score™ of 90/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Med Life's Beta is 0.3573.


Med Life  (BSE:M) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Med Life Beta Related Terms


Med Life Beta Historical Data

* Premium members only.

The historical data trend for Med Life's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med Life Beta Chart

Med Life Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.36 0.55 0.46 -0.17

Med Life Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.31 -0.36 -0.30 0.42

BSE:M vs HCA, THC, DVA: Beta Comparison

For the Medical Care Facilities subindustry, Med Life's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Med Life Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Beta distribution charts can be found below:

* The bar in red indicates where Med Life's Beta falls into.


BSE:M
90GF Score
Med Life SA BSE:M
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Med Life Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3573 mean?
Med Life (BSE:M) has a Beta of 0.3573 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Med Life and its competitors.
Is Med Life's Beta too high?
Med Life's current Beta is 0.3573. Overall, Med Life has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Beta compare to HCA and THC?
Med Life's Beta of 0.3573 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Med Life and its competitors. Med Life's current Beta is 0.3573. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.36 — trading 45.3% above its estimated fair value. The current Beta is 0.3573. Med Life's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Med Life (BSE:M), the current Beta is 0.3573 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Med Life (BSE:M) Overvalued in 2026?

Based on GuruFocus' analysis, Med Life stock appears to be overvalued. The current stock price of lei11.36 is trading 45.3% above its estimated GF Value™ of lei7.82. GuruFocus considers Med Life to be Significantly Overvalued.

Key valuation signals for BSE:M:

  • Beta: 0.3573
  • GF Value™: lei7.82 vs. price of lei11.36 (45.3% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Med Life Business Description

Other Exchanges 0RO5:UKO0C:Germany
Address Calea Grivitei, No. 365, District 1, Bucharest, ROU
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
90GF Score

Get the complete analysis for BSE:M

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei11.36
Price
lei7.82
GF Value